Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | MM has a bright future: highlights from ASH

Mark Bustoros, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses his highlights in the field of multiple myeloma (MM) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Bustoros points to the Phase III MAIA trial (NCT02252172), which evaluated the addition of daratumumab to lenalidomide/dexamethasone (D-Rd) vs. Rd alone in transplant-ineligible newly diagnosed MM. Dr Busteros also discusses other trials hoping to improve the outlook for patients and reshape the therapeutic landscape.